Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Comment by menoalittleon Jun 13, 2024 11:19am
138 Views
Post# 36087138

RE:RE:Not sure I wanted to bring this topic up (again.)

RE:RE:Not sure I wanted to bring this topic up (again.)>> The issue I see with a low ball take out offer is that there are more than one big pharma watching here. 

I strongly agree with that, which is why I think it would probably take at least $1.50/share, which would end up being around 1/2 billion (which is the figure I initially threw out here.)  Even it were to spark another offer, I think anything around $2/share is still very cheap for big pharma to offer - and probably much, much lower than management at TLT would like to get for it.  But, it's enough of an offer that I think that it would be a real challenge for Roger to defeat at this point.

So, to repeat... I'm inclined to think that anyone selling at these price levels is probably clueless as to the real potential of this stock to (otherwise unexpectedly) explode upwards the very near future as a result of what many here are suggesting is a "lowball offer."

<< Previous
Bullboard Posts
Next >>